



# **Sport en diabetes**


**Prof. dr. Dominique Hansen**

# Diabetes epidemie




## IDF DIABETES ATLAS

5<sup>th</sup> edition | 2012 update



# Diabetes epidemie


---




# Type 1 vs. type 2 diabetes

| Type 1 Diabetes                                                        | Type 2 Diabetes                                                                            |
|------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| 1. Young onset<br>(less than 35 years)                                 | Older onset                                                                                |
| 2. Rapid onset of<br>symptoms<br>(eg. ketoacidosis)                    | No obvious symptoms in<br>the early stage                                                  |
| 3. Non-obese                                                           | Obese                                                                                      |
| 4. Body cannot produce<br>insulin                                      | Insulin secretion can be<br>normal or abnormal,<br>Body cells are resistant<br>to insulin  |
| 5. Managed by insulin<br>injections, with diet and<br>exercise control | Managed by oral<br>medications or insulin<br>injections, with diet and<br>exercise control |

# Type 1 vs. type 2 diabetes




# Diabetes epidemie



# Diabetes epidemie

## Major diabetes complications



# Diabetes epidemie



QD1 How often do you exercise or play sport?

|                                                                                          | Regularly | With some regularity | Seldom | Never | Don't know |
|------------------------------------------------------------------------------------------|-----------|----------------------|--------|-------|------------|
| EU28                                                                                     | 8%        | 33%                  | 17%    | 42%   | 0%         |
|  Gender |           |                      |        |       |            |
| Man                                                                                      | 9%        | 36%                  | 18%    | 37%   | 0%         |
| Woman                                                                                    | 7%        | 30%                  | 16%    | 47%   | 0%         |
|  Age  |           |                      |        |       |            |
| 15-24                                                                                    | 11%       | 53%                  | 17%    | 19%   | 0%         |
| 25-39                                                                                    | 8%        | 38%                  | 21%    | 33%   | 0%         |
| 40-54                                                                                    | 8%        | 31%                  | 20%    | 41%   | 0%         |
| 55 +                                                                                     | 8%        | 22%                  | 12%    | 58%   | 0%         |

# Sport: waarom?

## Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study

Chi Pang Wen\*, Jackson Pui Man Wai\*, Min Kuang Tsai, Yi Chen Yang, Ting Yuan David Cheng, Meng-Chih Lee, Hui Ting Chan, Chwen Keng Tsao, Shan Pou Tsai, Xifeng Wu

416175 individuals

average follow-up of 8.05 years




Figure 2: Daily physical activity duration and all-cause mortality reduction

# Sport: waarom?

## Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study

Chi Pang Wen\*, Jackson Pui Man Wai\*, Min Kuang Tsai, Yi Chen Yang, Ting Yuan David Cheng, Meng-Chih Lee, Hui Ting Chan, Chwen Keng Tsao, Shan Pou Tsai, Xifeng Wu

416175 individuals

average follow-up of 8.05 years





Figure 2: Daily physical activity duration and all-cause mortality reduction

# Sport: waarom?

## Comparative effectiveness of exercise interventions on mortality outcomes: metaepidemiological study

Huseyin Naci,<sup>1,2</sup> John P A Ioannidis<sup>3</sup>





# Sport: waarom?

## Leisure Time Spent Sitting in Relation to Total Mortality in a Prospective Cohort of US Adults

Alpa V. Patel\*, Leslie Bernstein, Anusila Deka, Heather Spencer Feigelson, Peter T. Campbell, Susan M. Gapstur, Graham A. Colditz, and Michael J. Thun


184,190 participants



# Sport in type 2 diabetes: waarom?

## Prevention of type 2 diabetes


- 3234 glucose-intolerant subjects



Dagelijkse metformine inname =  
-33% T2DM risico

Verandering in levensstijl =  
-58% T2DM risico

# Sport in type 2 diabetes: waarom?



13.30h hyperglycemisch

0.4h hyperglycemisch



# Sport in type 2 diabetes: waarom?






**FIGURE 3**—The duration of hyperglycemia, (i.e., percentage of time [glucose] above  $10.0 \text{ mmol} \cdot \text{L}^{-1}$ ), 24 h before and after 45 min of circuit training. Values are expressed as means  $\pm$  SEM. \* Significantly different from values observed on day 1 (preexercise) ( $P < 0.05$ ).




# Sport in type 2 diabetes: waarom?

**Figure 1.** Absolute Changes in HbA<sub>1c</sub> of Individual Studies of Structured Exercise Training vs No Intervention



# Sport in type 2 diabetes: waarom?



# Sport in type 2 diabetes: waarom?

---

- Er zijn velerlei andere positieve effecten:
  - Kwaliteit van leven
  - Fysieke fitheid
  - Risico voor kanker
  - Risico voor dementie
  - Risico voor hart –en vaatziekten
    - Betere risicofactoren

# Sport in type 1 diabetes: waarom?

---



# Sport in type 1 diabetes: waarom?

## A systematic review and meta-analysis of exercise interventions in adults with type 1 diabetes

Jane E. Yardley<sup>a,b</sup>, Jacqueline Hay<sup>a</sup>, Ahmed M. Abou-Setta<sup>c,d</sup>,  
Seth D. Marks<sup>e</sup>, Jonathan McGavock<sup>a,\*</sup>




Fig. 2 – Post-treatment glycated hemoglobin (HbA<sub>1c</sub>).

**Table 3 – Secondary study outcomes.**

| Outcome Measure                        | Trials | Intervention | Control | Effect estimate (95% CI) | I <sup>2</sup> (uCI) |
|----------------------------------------|--------|--------------|---------|--------------------------|----------------------|
| Maximal oxygen uptake [12,22,23]       | 3      | 35           | 35      | MD 3.45 (0.59, 6.31)     | 0% (0%, 88%)         |
| Weight (kg) [21,24]                    | 2      | 24           | 19      | MD 1.10 (0.11, 2.10)     | 0%                   |
| Body mass index [22,24,26]             | 3      | 183          | 82      | MD -0.02 (-0.40, 0.37)   | 57% (0%, 88%)        |
| Insulin dose (U/kg) [22,26]            | 2      | 168          | 70      | MD -0.21 (-0.58, 0.16)   | 94%                  |
| High density lipoprotein [12,21,22,26] | 4      | 183          | 84      | SMD 0.34 (-0.56, 1.23)   | 85% (63%, 94%)       |
| Low density lipoprotein [12,21,22,26]  | 4      | 183          | 84      | SMD -0.02 (-0.29, 0.25)  | 0% (0%, 70%)         |
| Very low density lipoprotein [12]      | 1      | 6            | 7       | MD 0.00 (-0.14, 0.14)    | NE                   |
| Total cholesterol [12,21,26]           | 3      | 163          | 62      | SMD -0.72 (-1.70, 0.27)  | 77% (24%, 93%)       |
| Total triglycerides [12,21,26]         | 3      | 163          | 62      | SMD -0.57 (-1.19, 0.06)  | 48% (0%, 85%)        |
| Apolipoprotein (a) [12]                | 1      | 9            | 7       | MD 0.13 (-0.05, 0.31)    | NE                   |
| Apolipoprotein (b) [22]                | 1      | 20           | 22      | MD -0.07 (-0.19, 0.05)   | NE                   |

CI = confidence intervals;  $I^2$  = I-squared; MD = mean difference; SMD = standardized mean difference; uCI = uncertainty intervals around the I-squared statistic.

# Sport in type 2 diabetes: hoe?

---



# Trainingsintensiteit






Figure 4. Energy expenditure and fuel selection  
Values are means. FFA, free fatty acid.

# Trainingsintensiteit



# Trainingsintensiteit




# Sessieduur/volume

---


- Veronderstelling
  - Groter sportvolume = groter effect
    - Bloedsuikerspiegel daalt sterker

# Programmaduur




# Oefenfrequentie

dagen




Insulinegevoeligheid




Insulinegevoeligheid




# Oefenfrequentie



# Krachttraining?




# Krachttraining?




# Krachttraining?



Vs.



Myers J. et al. N Engl J Med 2002; 346:793-801.



Artero EG, et al. J Am Coll Cardiol. 2011; 57:1831-1837

# Sport in type 1 diabetes: hoe?

---

## Effects of Different Types of Acute and Chronic (Training) Exercise on Glycaemic Control in Type 1 Diabetes Mellitus

### A Meta-Analysis

*Cajsa Tonoli,<sup>1,2</sup> Elsa Heyman,<sup>2</sup> Bart Roelands,<sup>1,3</sup> Luk Buyse,<sup>1</sup> Stephen S. Cheung,<sup>4</sup> Serge Berthoin<sup>5</sup> and Romain Meeusen<sup>1</sup>*

**Table VIII.** Meta-analytic results for specific thresholds (volume, duration, intensity; additional recommendations; baseline glycaemic control) to gain significant improvement in glycated haemoglobin

| Training protocol                                            | Cohen's d | 95% CI LL | 95% CI UL | No. of studies | No. of subjects |
|--------------------------------------------------------------|-----------|-----------|-----------|----------------|-----------------|
| <b>Overall</b>                                               |           |           |           |                |                 |
| <3 mo of training                                            | -0.49     | -0.96     | 0.00      | 3              | 35              |
| =3 mo of training                                            | 0.06      | -0.26     | 0.39      | 6              | 73              |
| >3 mo of training                                            | -0.75     | -1.03     | -0.47     | 8              | 108             |
| <3 x/wk training                                             | -0.34     | -0.65     | -0.02     | 5              | 79              |
| ≥3 x/wk training                                             | -0.06     | -0.33     | 0.21      | 10             | 106             |
| Poor baseline glycaemic control (>8% HbA <sub>1c</sub> )     | -0.25     | -0.48     | -0.02     | 11             | 151             |
| Adequate baseline glycaemic control (<8% HbA <sub>1c</sub> ) | -0.02     | -0.64     | 0.6       | 1              | 20              |
| Increased $\dot{V}O_{2max}$ due to training programme        | -0.43     | -1.31     | 0.46      | 1              | 10              |
| No changes in $\dot{V}O_{2max}$ due to training programme    | -0.63     | -1.39     | 0.13      | 1              | 14              |
| <b>Aerobic training</b>                                      |           |           |           |                |                 |
| <3 mo of training                                            | -0.27     | -0.9      | 0.35      | 1              | 20              |
| =3 mo of training                                            | 0.13      | -0.21     | 0.47      | 5              | 67              |
| >3 mo of training                                            | -0.43     | -0.83     | -0.16     | 5              | 71              |
| Poor baseline glycaemic control (>8% HbA <sub>1c</sub> )     | -0.25     | -0.48     | -0.02     | 11             | 151             |
| Adequate baseline glycaemic control (<8% HbA <sub>1c</sub> ) | -0.02     | -0.64     | 0.6       | 1              | 20              |
| <3 x/wk training                                             | -0.63     | -0.97     | -0.29     | 5              | 69              |
| ≥3 x/wk training                                             | 0.00      | -0.3      | 0.31      | 7              | 82              |
| Increased $\dot{V}O_{2max}$ due to training programme        | -0.43     | -1.31     | 0.46      | 1              | 10              |
| No changes in $\dot{V}O_{2max}$ due to training programme    | -0.63     | -1.39     | 0.13      | 1              | 14              |
| Dietary advice                                               | 0.65      | -0.43     | 1.72      | 1              | 7               |
| No dietary advice                                            | -0.66     | -1.45     | 0.13      | 1              | 13              |
| <b>Resistance training</b>                                   |           |           |           |                |                 |
| <3 mo of training                                            | -0.93     | -1.96     | 0.09      | 1              | 8               |
| =3 mo of training                                            | -0.26     | -1.39     | 0.88      | 1              | 6               |
| <b>Mixed training</b>                                        |           |           |           |                |                 |
| Insulin and dietary advice                                   | -0.6      | -1.14     | -0.82     | 1              | 8               |
| No insulin and dietary advice                                | -0.23     | -1.16     | 0.69      | 1              | 9               |
| <3 d/wk                                                      | 0.82      | -0.09     | 1.73      | 1              | 10              |
| =3 d/wk                                                      | -0.2      | -0.87     | 0.48      | 2              | 17              |

**HbA<sub>1c</sub>** = glycated haemoglobin **LL** = lower limit; **UL** = upper limit;  $\dot{V}O_{2max}$  = maximal oxygen consumption.

# Sport in type 1 diabetes: hoe?

---



↳ Grotere vrijzetting van groeihormoon en adrenaline

↳ Verhoogde vrijzetting van glucose door lever

# Medische veiligheid van inspanning

---

- Perifere neuropathie en vertraagde wondgenezing
  - Wees alert voor voetwonden
- Autonome neuropathie
  - Stoornissen bloeddruk
- Hart –en vaatziekten
  - Stoornissen hartfunctie
- Retinopathie
  - Geen hoog-intense inspanning
- Nefropathie
  - Geen hoge bloeddrukken toelaten



# Medische veiligheid van inspanning

---

## Suikercontrole tijdens training

- Start trainingssessie
  - Glucose <75 mg/dl: suiker innemen
  - Glucose <100 mg/dl: wees alert voor hypoglycemie
  - Glucose >300 mg/dl: niet ok
- Risico's voor hypoglycemie tijdens inspanning
  - Hoog calorieverbruik
  - Training in nuchtere toestand?
  - Medicatie: sulfonyleurea, meglitinide, insuline

# Medische veiligheid van inspanning

Adjustments of Exogenous Insulin Therapy Dose Ahead of Exercise Training<sup>69</sup>

| Duration and Type of Exercise         | Glycemia Pre-exercise     | Insulin Adjustment Pre-exercise | Extra Glucose Intake During Exercise |
|---------------------------------------|---------------------------|---------------------------------|--------------------------------------|
| <30 min low-intensity exercise        | <5 mmol/L, <90 mg/dL      | Half dose                       | 10–15 g                              |
|                                       | >5 mmol/L, >90 mg/dL      | Normal dose                     | None                                 |
| 30–60 min moderate-intensity exercise | <5 mmol/L, <90 mg/dL      | Skip                            | 30–45 g                              |
|                                       | 5–10 mmol/L, 90–180 mg/dL | Half dose                       | 15 g                                 |
|                                       | >10 mmol/L, >180 mg/dL    | Normal dose                     | None                                 |
| >60 min moderate-intensity exercise   | <5 mmol/L, <90 mg/dL      | Skip                            | 45 g/h                               |
|                                       | 5–10 mmol/L, 90–180 mg/dL | Half dose                       | 30–45 g/h                            |
|                                       | >10 mmol/L, >180 mg/dL    | Half dose                       | 15 g/h                               |

# KineCoach project

---

## Physical Therapy

Journal of the American Physical Therapy Association

### **Exercise Assessment and Prescription in Patients With Type 2 Diabetes in the Private and Home Care Setting: Clinical Recommendations From AXXON (Belgian Physical Therapy Association)**


Dominique Hansen, Stefaan Peeters, Bruno Zwaenepoel, Dirk Verleyen, Carla Wittebrood, Nicole Timmerman, Michel Schotte

# KineCoach pr

KineCoach: nationaal  
bewegingsprogramma

DIABETES & BEWEGING

Figuur 1: Stappenplan bij het opzetten van bewegingsprogramma's voor personen met type 2 diabetes.





Contact: [Dominique.hansen@uhasselt.be](mailto:Dominique.hansen@uhasselt.be)